582 related articles for article (PubMed ID: 32474328)
21. m6A-Related Genes Contribute to Poor Prognosis of Hepatocellular Carcinoma.
Zou Y; Jiang G; Xie Y; Li H
Comput Math Methods Med; 2022; 2022():2427987. PubMed ID: 36339682
[TBL] [Abstract][Full Text] [Related]
22. Gene and prognostic value of N6-methyladenosine (m6A) modification regulatory factors in lung adenocarcinoma.
Zhang D; Zhang D; Wang C; Yang X; Zhang R; Li Q; Xiong Y
Eur J Cancer Prev; 2022 Jul; 31(4):354-362. PubMed ID: 34519693
[TBL] [Abstract][Full Text] [Related]
23. Bioinformatic analyses and experimental validation of the role of m6A RNA methylation regulators in progression and prognosis of adrenocortical carcinoma.
Xu F; Guan Y; Ma Y; Xue L; Zhang P; Yang X; Chong T
Aging (Albany NY); 2021 Apr; 13(8):11919-11941. PubMed ID: 33952721
[TBL] [Abstract][Full Text] [Related]
24. Gene Signature and Identification of Clinical Trait-Related m
Hou J; Wang Z; Li H; Zhang H; Luo L
Front Genet; 2020; 11():522. PubMed ID: 32754191
[TBL] [Abstract][Full Text] [Related]
25. The YTH Domain Family of N6-Methyladenosine "Readers" in the Diagnosis and Prognosis of Colonic Adenocarcinoma.
Xu D; Shao J; Song H; Wang J
Biomed Res Int; 2020; 2020():9502560. PubMed ID: 32596399
[TBL] [Abstract][Full Text] [Related]
26. Effects of m6A RNA methylation regulators on endometrial cancer.
Zhang Y; Yang Y
J Clin Lab Anal; 2021 Sep; 35(9):e23942. PubMed ID: 34347888
[TBL] [Abstract][Full Text] [Related]
27. N6-methyladenosine RNA methylation regulator-related alternative splicing gene signature as prognostic predictor and in immune microenvironment characterization of patients with low-grade glioma.
Maimaiti A; Tuersunniyazi A; Meng X; Pei Y; Ji W; Feng Z; Jiang L; Wang Z; Kasimu M; Wang Y; Shi X
Front Genet; 2022; 13():872186. PubMed ID: 35937991
[No Abstract] [Full Text] [Related]
28. Role of global aberrant alternative splicing events in papillary thyroid cancer prognosis.
Lin P; He RQ; Huang ZG; Zhang R; Wu HY; Shi L; Li XJ; Li Q; Chen G; Yang H; He Y
Aging (Albany NY); 2019 Apr; 11(7):2082-2097. PubMed ID: 30986203
[TBL] [Abstract][Full Text] [Related]
29. METTL16 inhibits papillary thyroid cancer tumorigenicity through m
Li Q; Wang Y; Meng X; Wang W; Duan F; Chen S; Zhang Y; Sheng Z; Gao Y; Zhou L
Cell Mol Life Sci; 2024 Feb; 81(1):81. PubMed ID: 38334797
[TBL] [Abstract][Full Text] [Related]
30. FTO suppresses glycolysis and growth of papillary thyroid cancer via decreasing stability of APOE mRNA in an N6-methyladenosine-dependent manner.
Huang J; Sun W; Wang Z; Lv C; Zhang T; Zhang D; Dong W; Shao L; He L; Ji X; Zhang P; Zhang H
J Exp Clin Cancer Res; 2022 Jan; 41(1):42. PubMed ID: 35090515
[TBL] [Abstract][Full Text] [Related]
31. The m
Romanowska K; Rawłuszko-Wieczorek AA; Marczak Ł; Kosińska A; Suchorska WM; Golusiński W
Biomolecules; 2021 Jun; 11(6):. PubMed ID: 34207099
[TBL] [Abstract][Full Text] [Related]
32. Identification of a Two-m6A RNA Methylation Regulator Risk Signature as an Independent Prognostic Biomarker in Papillary Renal Cell Carcinoma by Bioinformatic Analysis.
Yang F; Zhao G; Ge L; Song Y; Hong K; Zhang H; Liu C; Hong P; Ma L
Biomed Res Int; 2021; 2021():4582082. PubMed ID: 33628782
[TBL] [Abstract][Full Text] [Related]
33. Development of prognostic signatures for intermediate-risk papillary thyroid cancer.
Brennan K; Holsinger C; Dosiou C; Sunwoo JB; Akatsu H; Haile R; Gevaert O
BMC Cancer; 2016 Sep; 16(1):736. PubMed ID: 27633254
[TBL] [Abstract][Full Text] [Related]
34. Construction and Validation of an m6A RNA Methylation Regulators-Based Prognostic Signature for Esophageal Cancer.
Xu LC; Pan JX; Pan HD
Cancer Manag Res; 2020; 12():5385-5394. PubMed ID: 32753956
[TBL] [Abstract][Full Text] [Related]
35. Identification of ferroptosis genes in immune infiltration and prognosis in thyroid papillary carcinoma using network analysis.
Lin R; Fogarty CE; Ma B; Li H; Ni G; Liu X; Yuan J; Wang T
BMC Genomics; 2021 Jul; 22(1):576. PubMed ID: 34315405
[TBL] [Abstract][Full Text] [Related]
36. N
von Hagen F; Gundert L; Strick A; Klümper N; Schmidt D; Kristiansen G; Tolkach Y; Toma M; Ritter M; Ellinger J
Mol Carcinog; 2021 May; 60(5):354-362. PubMed ID: 33755994
[TBL] [Abstract][Full Text] [Related]
37. Clinical and prognostic pan-cancer analysis of m6A RNA methylation regulators in four types of endocrine system tumors.
Li K; Luo H; Luo H; Zhu X
Aging (Albany NY); 2020 Nov; 12(23):23931-23944. PubMed ID: 33237039
[TBL] [Abstract][Full Text] [Related]
38. Construction and clinical evaluation of N6-methyladenosine risk signature of YTHDC2, IGF2BP2, and HNRNPC in head and neck squamous cell carcinoma.
Yue Q; Xu L; Zhang D
Hua Xi Kou Qiang Yi Xue Za Zhi; 2022 Dec; 40(6):704-709. PubMed ID: 36416324
[TBL] [Abstract][Full Text] [Related]
39. m6A regulators are associated with osteosarcoma metastasis and have prognostic significance: A study based on public databases.
Zhang W; Wang L; Zhang P; Zhang Q
Medicine (Baltimore); 2021 May; 100(20):e25952. PubMed ID: 34011074
[TBL] [Abstract][Full Text] [Related]
40. Gene Characteristics and Prognostic Values of m
Li N; Chen X; Liu Y; Zhou T; Li W
J Healthc Eng; 2021; 2021():2257066. PubMed ID: 34367534
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
